CGH:炎症性肠病患者炎性标志物与结肠癌风险相关

2014-02-21 cmt 丁香园

C反应蛋白(CRP)水平与红细胞沉降率(ESR)升高的炎症性肠病(IBD)患者的结直肠癌(CRC)风险显著增加;多变量分析显示,高CRP分位数患者的CRC风险显著增加,高ESR也与CRC高风险呈独立相关;持续强化监测策略可使CRC高风险患者受益,而对于低风险患者,可考虑减少结肠镜检查频次。 日前一项研究显示,C反应蛋白(CRP)水平与红细胞沉降率(ESR)升高的炎症性肠病(IBD)患者的

C反应蛋白(CRP)水平与红细胞沉降率(ESR)升高的炎症性肠病(IBD)患者的结直肠癌(CRC)风险显著增加;多变量分析显示,高CRP分位数患者的CRC风险显著增加,高ESR也与CRC高风险呈独立相关;持续强化监测策略可使CRC高风险患者受益,而对于低风险患者,可考虑减少结肠镜检查频次。【原文下载

日前一项研究显示,C反应蛋白(CRP)水平与红细胞沉降率(ESR)升高的炎症性肠病(IBD)患者的结直肠癌(CRC)风险显著增加,研究提示,上述两个指标均可作为结肠癌风险的标志物。Clinical Gastroenterology and Hepatology期刊1月6日在线版发表了来自美国波士顿的研究者的上述前瞻性研究成果。

研究者基于患者中位CRP水平和中位ESR的差异,分别将3,145 例和4,008例IBD患者分为四组,然后进行随访,中位随访时间6年。多变量分析显示,高CRP分位数患者的CRC风险显著增加,高ESR也与CRC高风险呈独立相关。

波士顿麻省总医院胃肠病专家Ashwin Ananthakrishnan医生领导的研究小组认为,上述相关性以及其他临床变量有助于患者风险分层。确认患者风险程度非常重要,持续强化监测策略可使CRC高风险患者受益,而对于低风险患者,可考虑减少结肠镜检查频次。每位患者的炎症严重程度或有助于制定个体化监测方案,甚至还有益于治疗应答等其他结局的监测。

研究者发现,在校正年龄、性别、种族、IBD类型及其他因素后,最高CRP四分位组患者CRC风险是最低四分位数患者的2倍。无论男性还是女性、克罗恩病还是溃疡性结肠炎患者,这一关联强度均相似。

同样,最高ESR四分位数患者CRC风险也是最低四分位数患者的2倍,溃疡性结肠炎及男性患者关联性最强。每个分位数患者中位CRP值分别为0.8 mg/L、2.7 mg/L、7.5 mg/L和32.8 mg/L,中位ESR值分别为7 mm/hr、14 mm/hr、25 mm/hr和50 mm/hr。

总体而言,CRP队列和ESR队列中分别有33例和102例患者发展为结直肠癌,确诊时中位年龄为55岁。中位CRP检测次数为3次,中位ESR检测次数为6次。半数以上的患者为女性,大多数为白人,溃疡性结肠炎患者略多于克罗恩病患者。

研究者观察到,在校正结肠镜检查次数、医疗服务利用强度、类固醇使用情况以及其他因素后,无论CRP队列还是ESR队列,上述结果均是如此。

原始出处

Ananthakrishnan AN1, Cheng SC2, Cai T2, Cagan A3, Gainer VS3, Szolovits P4, Shaw SY5, Churchill S6, Karlson EW7, Murphy SN8, Kohane I9, Liao KP7.Serum Inflammatory Markers and Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases.Clin Gastroenterol Hepatol. 2014 Jan 7.【原文下载

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1840789, encodeId=d15b1840e89f3, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jun 09 08:30:00 CST 2014, time=2014-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061423, encodeId=7156206142329, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Apr 17 15:30:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058347, encodeId=8464205834e24, content=<a href='/topic/show?id=f6ba4546d1' target=_blank style='color:#2F92EE;'>#CGH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4546, encryptionId=f6ba4546d1, topicName=CGH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat May 03 00:30:00 CST 2014, time=2014-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546994, encodeId=da2b15469947b, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Sun Feb 23 00:30:00 CST 2014, time=2014-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599959, encodeId=c100159995947, content=<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9fa18776644, createdName=huangshifeng, createdTime=Sun Feb 23 00:30:00 CST 2014, time=2014-02-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1840789, encodeId=d15b1840e89f3, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jun 09 08:30:00 CST 2014, time=2014-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061423, encodeId=7156206142329, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Apr 17 15:30:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058347, encodeId=8464205834e24, content=<a href='/topic/show?id=f6ba4546d1' target=_blank style='color:#2F92EE;'>#CGH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4546, encryptionId=f6ba4546d1, topicName=CGH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat May 03 00:30:00 CST 2014, time=2014-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546994, encodeId=da2b15469947b, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Sun Feb 23 00:30:00 CST 2014, time=2014-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599959, encodeId=c100159995947, content=<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9fa18776644, createdName=huangshifeng, createdTime=Sun Feb 23 00:30:00 CST 2014, time=2014-02-23, status=1, ipAttribution=)]
    2014-04-17 sjq027
  3. [GetPortalCommentsPageByObjectIdResponse(id=1840789, encodeId=d15b1840e89f3, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jun 09 08:30:00 CST 2014, time=2014-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061423, encodeId=7156206142329, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Apr 17 15:30:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058347, encodeId=8464205834e24, content=<a href='/topic/show?id=f6ba4546d1' target=_blank style='color:#2F92EE;'>#CGH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4546, encryptionId=f6ba4546d1, topicName=CGH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat May 03 00:30:00 CST 2014, time=2014-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546994, encodeId=da2b15469947b, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Sun Feb 23 00:30:00 CST 2014, time=2014-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599959, encodeId=c100159995947, content=<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9fa18776644, createdName=huangshifeng, createdTime=Sun Feb 23 00:30:00 CST 2014, time=2014-02-23, status=1, ipAttribution=)]
    2014-05-03 chendoc242
  4. [GetPortalCommentsPageByObjectIdResponse(id=1840789, encodeId=d15b1840e89f3, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jun 09 08:30:00 CST 2014, time=2014-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061423, encodeId=7156206142329, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Apr 17 15:30:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058347, encodeId=8464205834e24, content=<a href='/topic/show?id=f6ba4546d1' target=_blank style='color:#2F92EE;'>#CGH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4546, encryptionId=f6ba4546d1, topicName=CGH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat May 03 00:30:00 CST 2014, time=2014-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546994, encodeId=da2b15469947b, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Sun Feb 23 00:30:00 CST 2014, time=2014-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599959, encodeId=c100159995947, content=<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9fa18776644, createdName=huangshifeng, createdTime=Sun Feb 23 00:30:00 CST 2014, time=2014-02-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1840789, encodeId=d15b1840e89f3, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Jun 09 08:30:00 CST 2014, time=2014-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061423, encodeId=7156206142329, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Thu Apr 17 15:30:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058347, encodeId=8464205834e24, content=<a href='/topic/show?id=f6ba4546d1' target=_blank style='color:#2F92EE;'>#CGH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4546, encryptionId=f6ba4546d1, topicName=CGH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat May 03 00:30:00 CST 2014, time=2014-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546994, encodeId=da2b15469947b, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Sun Feb 23 00:30:00 CST 2014, time=2014-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599959, encodeId=c100159995947, content=<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9fa18776644, createdName=huangshifeng, createdTime=Sun Feb 23 00:30:00 CST 2014, time=2014-02-23, status=1, ipAttribution=)]

相关威廉亚洲官网

NEJM:肿瘤坏死因子抑制剂在炎症性肠病治疗中的应用

文章要点: 丹麦哥本哈根大学健康和医学科学院海莱乌医院胃肠病科Ole Haagen Nielsen等医生以一个病例为中心,在本文中对TNF-α用于治疗炎症性肠病的各种临床应用问题、治疗机制、疗效以及可能存在的副作用进行了讨论和综述。在文章的最后作者给出了对该类患者进行治疗的建议。 病例介绍: 35岁男性患者。患有进展性克罗恩氏回肠及结肠炎。该患者8年前诊断患有克罗恩病,之前已进行过3个疗

Arch Surg:接受手术的炎症性肠病患者静脉血栓栓塞风险高

      《外科学文献》(Archives of Surgery)10月17日在线发表的一项回顾性队列研究显示,接受手术治疗的炎症性肠病(IBD)患者发生深静脉血栓形成(DVT)或肺栓塞(PE)的风险是非IBD患者的2倍,并且接受非肠道手术的IBD患者该风险更大。因此,对于接受手术的IBD患者,应考虑采取标准DVT和PE预防措施。    &nbs

炎症性肠病顺序性药物治疗路径

近年来炎症性肠病(IBD)药物治疗进展较快[1-3]。但目前仍有较多患者未得到有效治疗,其原因与以下因素有关:治疗开始时未 制定具有预期目标的治疗方案;反复使用不能达到有效控制炎症作用的药物,或同时使用多种作用机制不同的药物叠加治疗,剂量低,治疗不足,疗效欠佳,而副作 用增多;治疗过程中随意变更药物或治疗方案,或患者治疗依从性差,使肠道病变未能得到有效控制,长期处于慢性活动状态,最终产生严重或

Gastroenterology :荟萃分析显示炎症性肠病(IBD)患者手术风险与时间的关系

2013年11月刊发在Gastroenterology杂志上的一项基于人群的研究显示,在过去的60年里,炎症性肠病(IBD)患者需要接受肠切除手术的风险已逐渐降低。IBD是一组病因尚未明确,以慢性复发性的肠道炎症为特征的疾病,主要包括克罗恩病(CD)和溃疡性结肠炎(UC)。对于内科治疗无效的IBD患者,通常需要接受手术治疗。但是随着时间的推移,IBD患者需要接受手术治疗的风险并不明确。来自加拿大卡